Preferred Label : Daraxonrasib;
NCIt synonyms : RASMUTLI(ON) Inhibitor RMC-6236; Ras-selective Tri-complex Inhibitor RMC-6236; RAS Inhibitor RMC-6236;
NCIt definition : An orally bioavailable inhibitor of the active, guanosine triphosphate (GTP)-bound
form of both wild type and mutant variants of the RAS isoforms, including HRAS, NRAS
and KRAS, with potential antineoplastic activity. Upon oral administration, daraxonrasib
binds to an intracellular chaperone protein, cyclophilin A (CypA). The resulting inhibitory
binary complex binds to active, GTP-bound RAS to form a tri-complex. This tri-complex
inhibits RAS-dependent signaling and inhibits the proliferation of tumor cells in
which RAS is overexpressed and/or mutated. RAS plays an important role in cell signaling,
division and differentiation. Mutations of RAS may induce constitutive signal transduction
leading to tumor cell growth, proliferation, invasion, and metastasis.;
UNII : B6T47Y2UAP;
CAS number : 2765081-21-6;
Molecule name : RMC-6236; RMC 6236;
NCI Metathesaurus CUI : CL1792828;
Origin ID : C188048;
UMLS CUI : C5706445;
Semantic type(s)
- concept_is_in_subset
- has_target
